Losartan potassium is marketed as a single-ingredient ... in patients with renal impairment (creatinine clearance [CL cr], <30 mL/min).

to support the commercial launch of Arbli ™ (losartan potassium) Oral Suspension, while simultaneously announcing a temporary suspension of further ELOC draws for the next 30 trading days or ...

Scienture Holdings, Inc. announced the initiation of supply chain activities by its subsidiary, Scienture, LLC, to manufacture ArbliTM (losartan potassium) Oral Suspension in preparation for its ...